USA flag logo/image

An Official Website of the United States Government

Novel Proteomic Arrays of In Vitro Expressed Proteins for Autoimmune Disease

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60540
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
AI052525
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AMBERGEN, INC
AMBERGEN, INC 313 PLEASANT ST WATERTOWN, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2007
Title: Novel Proteomic Arrays of In Vitro Expressed Proteins for Autoimmune Disease
Agency: HHS
Contract: 2R44AI052525-03A1
Award Amount: $1,972,749.00
 

Abstract:

DESCRIPTION (provided by applicant): Progress in sequencing the human genome has led to a new goal - expressing and characterizing the human proteome. A promising area where proteomics can have a major impact is autoimmune disease. Proteome-wide screening against sera from patients with particular autoimmune diseases can enable the discovery of new autoantigens, the development of microarray-based diagnostic assays, and effective treatments for autoimmune disease. During Phase I, we developed a novel, low-c ost, high throughput approach for proteomics based on Bead Sorted Libraries of In Vitro Expressed Proteins (BS-LIVE- PRO). These protein libraries can be expressed inexpensively in a single cell-free translation reaction using a Bead Sorted Library of In V itro Expressible DNA (BS-LIVE-DNA) as a template. Additional novel technologies developed during Phase I which augment this approach include: i) solid-phase PCR to produce BS-LIVE-DNA from cDNA libraries, ii) a method (PC-PRINT) to rapidly phototransfer th e protein on each bead in the BS-LIVE-PRO onto discrete spots on a microarray surface using proprietary photocleavable linkers, and iii) methods to decode the randomly arrayed spots generated by PC-PRINT using photo-transferable DNA or mass-tags (PC-CODE). We propose to extensively optimize and evaluate this new technology during Phase II with the aim of commercializing BS-LIVE-PRO. We will apply BS-LIVEPRO to autoimmune diseases in collaboration with Dr. Donald Bloch at the Massachusetts General Hospital, a leading expert on autoantigen discovery and primary biliary cirrhosis. Similar studies will be carried out on other vasculitis autoimmune diseases in association with Dr. Peter Merkel, Director of the Vasculitis Research Consortium. Proteome-wide scr eening against sera from patients with particular autoimmune diseases can lead to the discovery of new autoantigens, the development of diagnostic assays to identify autoimmune disease and, ultimately, improved treatments. We have developed a novel, low-co st, high throughput approach for proteomics based on Bead Sorted Libraries of In Vitro Expressed Proteins (BS-LIVE-PRO). We propose to extensively optimize and evaluate this new technology during Phase II with the aim of commercializing diagnostic assays f or autoimmune diseases.

Principal Investigator:

Mark Lim
6179239930
MLIM@AMBERGEN.COM

Business Contact:

Shella Batelman
shella@ambergen.com
Small Business Information at Submission:

AMBERGEN, INC
313 Pleasant Street Watertown, MA 02472

EIN/Tax ID: 043228005
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No